MCID: LMY004
MIFTS: 55

Leiomyosarcoma malady

Categories: Rare diseases, Cancer diseases, Muscle diseases

Aliases & Classifications for Leiomyosarcoma

Aliases & Descriptions for Leiomyosarcoma:

Name: Leiomyosarcoma 12 50 56 52 42 14 69
Leiomyosarcomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1967
MeSH 42 D007890
NCIt 47 C3158
Orphanet 56 ORPHA64720
MESH via Orphanet 43 D007890
UMLS via Orphanet 70 C0023269
ICD10 via Orphanet 34 C49.9
UMLS 69 C0023269

Summaries for Leiomyosarcoma

NIH Rare Diseases : 50 leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. leiomyosarcoma is a type of sarcoma. it spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. the exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. it is most often found in the uterus or abdomen. last updated: 6/26/2015

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to heart leiomyosarcoma and granular cell leiomyosarcoma. An important gene associated with Leiomyosarcoma is CHEK2 (Checkpoint Kinase 2), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and liver, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Disease Ontology : 12 A malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 71 Leiomyosarcoma (Gr. \"smooth muscle connective tissue tumor\"), also referred to as LMS, is a malignant... more...

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)
id Related Disease Score Top Affiliating Genes
1 heart leiomyosarcoma 33.1 DES MYOG
2 granular cell leiomyosarcoma 33.0 ENO2 MUC1 S100B
3 vagina leiomyosarcoma 32.9 ACTC1 DES FH MUC1
4 larynx leiomyosarcoma 32.7 ENO2 IGF2 KIT PDGFRA
5 gastrointestinal stromal tumor 31.0 ACTC1 DES ENO2 KIT PDGFRA PDGFRB
6 endometrial stromal sarcoma 30.5 MUC1 PGR VIM
7 myoma 29.8 ACTC1 DES MUC1 S100B VIM
8 mesenchymoma 29.7 KIT MUC1 PGR VIM
9 desmoid tumor 29.5 ACTC1 MUC1 S100B VIM
10 meige syndrome 29.2 ENO2 KIT MUC1 PDGFRA TP53
11 lung leiomyosarcoma 12.1
12 liver leiomyosarcoma 12.1
13 colon leiomyosarcoma 12.0
14 kidney leiomyosarcoma 12.0
15 uterus leiomyosarcoma 12.0
16 extrahepatic bile duct leiomyosarcoma 11.9
17 mediastinum leiomyosarcoma 11.9
18 anus leiomyosarcoma 11.9
19 cutaneous leiomyosarcoma 11.9
20 epithelioid leiomyosarcoma 11.9
21 pulmonary artery leiomyosarcoma 11.9
22 gastric leiomyosarcoma 11.9
23 myxoid leiomyosarcoma 11.9
24 retroperitoneal leiomyosarcoma 11.9
25 breast leiomyosarcoma 11.9
26 prostate leiomyosarcoma 11.9
27 inflammatory leiomyosarcoma 11.8
28 vulvar leiomyosarcoma 11.8
29 pulmonary vein leiomyosarcoma 11.8
30 bone leiomyosarcoma 11.8
31 leiomyosarcoma of the cervix uteri 11.8
32 small intestine leiomyosarcoma 11.7
33 conventional leiomyosarcoma 11.7
34 superior vena cava leiomyosarcoma 11.7
35 rectum leiomyosarcoma 11.7
36 gallbladder leiomyosarcoma 11.7
37 esophagus leiomyosarcoma 11.7
38 fallopian tube leiomyosarcoma 11.7
39 central nervous system leiomyosarcoma 11.7
40 uterine corpus myxoid leiomyosarcoma 11.7
41 ovary leiomyosarcoma 11.7
42 uterine corpus epithelioid leiomyosarcoma 11.7
43 leiomyomatosis and renal cell cancer 10.9
44 vascular cancer 10.9
45 urachal cancer 10.7
46 paragangliomas 1, with or without deafness 10.7
47 fallopian tube carcinoma 10.7
48 carney triad 10.6
49 lymphomatoid papulosis 10.4 ACTC1 VIM
50 13q12.3 microdeletion syndrome 10.4 ACTC1 DES VIM

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma

Symptoms & Phenotypes for Leiomyosarcoma

GenomeRNAi Phenotypes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 WT1 S100B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.95 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.95 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.95 CHEK2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.95 CDK4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 CHEK2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.95 WT1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 CHEK2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.95 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 KIT WT1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.95 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.95 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.95 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.95 VIM
15 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.95 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.95 VIM
17 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.95 CHEK2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.95 CDK4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.95 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.95 VIM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.95 VIM KIT WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.95 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 KIT CDK4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 WT1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.95 CDK4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.95 WT1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 S100B VIM
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 CHEK2 VIM KIT WT1 CDK4 S100B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.95 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.95 KIT
32 Decreased substrate adherent cell growth GR00193-A-1 9.76 KIT
33 Decreased substrate adherent cell growth GR00193-A-2 9.76 CDK4 KIT
34 Decreased substrate adherent cell growth GR00193-A-3 9.76 CDK4 CHEK2
35 Decreased substrate adherent cell growth GR00193-A-4 9.76 CDK4 CHEK2 KIT
36 Increased cell viability after pRB stimulation GR00230-A-1 9.26 CHEK2 KIT PDGFRB CDK4

MGI Mouse Phenotypes related to Leiomyosarcoma:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 WT1 DES CDK4 ENO2 FH IGF2
2 homeostasis/metabolism MP:0005376 10.45 WT1 DES CDK4 FH IGF2 CHEK2
3 behavior/neurological MP:0005386 10.42 DES ENO2 CDK4 KIT MDM2 IGF2
4 cardiovascular system MP:0005385 10.41 WT1 DES CDK4 IGF2 ACTC1 MB
5 growth/size/body region MP:0005378 10.36 WT1 ACTC1 CAPN6 ENO2 CDK4 IGF2
6 mortality/aging MP:0010768 10.36 WT1 DES CDK4 FH CHEK2 ACTC1
7 embryo MP:0005380 10.35 WT1 CDK4 IGF2 MB KIT MDM2
8 hematopoietic system MP:0005397 10.31 WT1 CDK4 CHEK2 MB KIT IGF2
9 muscle MP:0005369 10.31 WT1 CAPN6 DES CDK4 IGF2 ACTC1
10 endocrine/exocrine gland MP:0005379 10.26 WT1 CDK4 CHEK2 IGF2 KIT PDGFRA
11 immune system MP:0005387 10.25 WT1 VIM CHEK2 CDK4 IGF2 KIT
12 craniofacial MP:0005382 10.19 CAPN6 ENO2 KIT IGF2 PDGFRB MDM2
13 integument MP:0010771 10.19 CDK4 KIT MDM2 IGF2 MYOG PDGFRB
14 digestive/alimentary MP:0005381 10.18 CAPN6 CDK4 IGF2 KIT PDGFRA MDM2
15 normal MP:0002873 10.06 WT1 CDK4 ACTC1 KIT MDM2 MYOG
16 limbs/digits/tail MP:0005371 10.02 IGF2 KIT PDGFRA MDM2 TP53 PGR
17 neoplasm MP:0002006 10.01 WT1 CDK4 CHEK2 KIT MDM2 PDGFRA
18 no phenotypic analysis MP:0003012 9.97 WT1 IGF2 KIT PDGFRA MYOG MDM2
19 renal/urinary system MP:0005367 9.81 WT1 CDK4 FH KIT MDM2 IGF2
20 pigmentation MP:0001186 9.65 CDK4 KIT MDM2 PDGFRA TP53
21 reproductive system MP:0005389 9.65 WT1 CDK4 IGF2 KIT PDGFRB MDM2
22 respiratory system MP:0005388 9.28 WT1 ENO2 MB KIT IGF2 MYOG

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2 Liver Extracts Phase 4,Phase 3,Phase 1
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
6
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
7
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
8
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
10
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
11
Lenograstim Approved Phase 3,Phase 2 135968-09-1
12
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
13
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
15
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
16
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
17
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
20
Ondansetron Approved Phase 3 99614-02-5 4595
21
Cyproheptadine Approved Phase 3 129-03-3 2913
22
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
23
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
24
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
25 Alkylating Agents Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
29 Isophosphamide mustard Phase 3,Phase 2,Phase 1
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Antimetabolites Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
36 Antimitotic Agents Phase 3,Phase 2,Phase 1
37 Antiviral Agents Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
40 Adjuvants, Immunologic Phase 3,Phase 2
41 Antibodies Phase 3,Phase 2,Phase 1
42 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
43 Endothelial Growth Factors Phase 3,Phase 2
44 Immunoglobulin G Phase 3
45 Immunoglobulins Phase 3,Phase 2,Phase 1
46 Mitogens Phase 3,Phase 2
47 Etoposide phosphate Phase 3,Phase 2
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1
49 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 143)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
4 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3
5 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Completed NCT01012297 Phase 3
6 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
9 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
10 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
11 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
12 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
13 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
15 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
16 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
17 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Recruiting NCT01533207 Phase 3
18 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3
19 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
20 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
21 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Active, not recruiting NCT01692678 Phase 3
22 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3
23 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
24 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3
25 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Not yet recruiting NCT03016819 Phase 3
26 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
27 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
28 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2
29 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2
30 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
31 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
32 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2
33 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2
34 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2
35 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2
36 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2
37 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2
38 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2
39 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Completed NCT00310518 Phase 2
40 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2
41 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2
42 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2
43 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2
44 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2
45 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2
46 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
47 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2
48 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2
49 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
50 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Genetic Tests for Leiomyosarcoma

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

39
Uterus, Smooth Muscle, Liver, Lung, Breast, Bone, Colon

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 1174)
id Title Authors Year
1
Primary Cutaneous Leiomyosarcoma Arising in a Patient With Li-Fraumeni Syndrome. A Neoplasm With Unusual Histopathologic Features and Loss of Heterozygosity at TP53 Gene. ( 28475508 )
2017
2
Myxoid leiomyosarcoma of the uterus: a clinicopathological and immunohistochemical study of 10 cases. ( 27717885 )
2017
3
Chronic paroxysmal headache secondary to an orbital metastatic leiomyosarcoma: A case report. ( 28058942 )
2017
4
Biatrial High-Grade Leiomyosarcoma With Nine-Year Post-Surgical Survival. ( 28007271 )
2017
5
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
6
Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22. ( 28476787 )
2017
7
Paratesticular Leiomyosarcoma: A Case Report and Review of the Literature. ( 28083483 )
2017
8
Laparoscopically assisted resection of a primary hepatic leiomyosarcoma: A safe approach in a rare malignancy. ( 28065534 )
2017
9
Transanal total mesorectal excision for a large leiomyosarcoma at the lower rectum: a case report and literature review. ( 28092017 )
2017
10
Transdifferentiation of pancreatic stromal tumor into leiomyosarcoma with metastases to liver and peritoneum: a case report. ( 27955634 )
2016
11
A Rare Intramedullary Spinal Cord Metastasis from a Retroperitoneal Leiomyosarcoma Presenting as a Non-Traumatic Spinal Cord Injury. ( 27820732 )
2016
12
Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor I^-independent mechanism. ( 27664035 )
2016
13
Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma. ( 27105972 )
2016
14
Prognostic Differences: Epstein-Barr Virus Associated Primary Leiomyosarcoma of the Spine versus Spinal Leiomyosarcoma Metastases. ( 28011357 )
2016
15
Role of surgery in the multimodal treatment of primary and recurrent leiomyosarcoma of the inferior vena cava. ( 27062161 )
2016
16
Response to Letter to the Editor re: Cananzi, et al.-Surgery of leiomyosarcoma of the inferior vena cava. ( 27189445 )
2016
17
Primary Leiomyosarcoma of the Pancreas-a Case Report and a Comprehensive Review. ( 27631424 )
2016
18
Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up. ( 27234428 )
2016
19
Case Report: Collision Tumour of Colon Leiomyosarcoma and Adenocarcinoma. ( 27504346 )
2016
20
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. ( 27882721 )
2016
21
Cardiac Metastasis of Leiomyosarcoma Complicated with Complete Atrio-Ventricular Block and Ventricular Tachycardia. ( 27014358 )
2016
22
Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib. ( 27079325 )
2016
23
Coexistence of psoriasis and primary high-grade subcutaneous leiomyosarcoma. ( 27990398 )
2016
24
Lumbar paraspinal primary high-grade leiomyosarcoma mimicking an extraforaminal schwannoma. ( 27625268 )
2016
25
Long term follow-up of surgery management of prostate leiomyosarcoma metastasized to the rib: A case report and literature review. ( 27330784 )
2016
26
Surgical Resection of a Leiomyosarcoma Involving Atrial Reconstruction, Cardiopulmonary Bypass, and Ex-Vivo Liver Resection and Reimplantation. ( 27645825 )
2016
27
Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells in vitro and in vivo. ( 26723257 )
2016
28
Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6A Months With Ulipristal Acetate and Contained Power Morcellation. ( 27539216 )
2016
29
Can the Right Kidney be Salvaged in the Surgical Management of Leiomyosarcoma of the Inferior Vena Cava-a Rare Case Report. ( 27651700 )
2016
30
The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. ( 27043847 )
2016
31
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma. ( 27149024 )
2016
32
Radiation-induced Leiomyosarcoma of the Oral Cavity: A Rare Occurrence Detected on 18F-FDG PET/CT. ( 27651746 )
2016
33
Pulmonary artery intramural leiomyosarcoma mimicking pulmonary aneurysm. ( 27926467 )
2016
34
Leiomyosarcoma Involving the Pancreas Diagnosed by Endoscopic Ultrasound Fine-Needle Aspiration. ( 28032292 )
2016
35
Primary Leiomyosarcoma in the Inferior Vena Cava Extended to the Right Atrium: A Case Report and Review of the Literature. ( 27920691 )
2016
36
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. ( 26891131 )
2016
37
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue. ( 26851003 )
2016
38
Diffusion-Weighted Imaging for Differentiating Uterine Leiomyosarcoma From Degenerated Leiomyoma. ( 27997438 )
2016
39
RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis. ( 26612755 )
2016
40
Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance. ( 27607470 )
2016
41
A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib. ( 27578036 )
2016
42
Multidetector computed tomography features of pancreatic metastases from leiomyosarcoma: Experience at a tertiary cancer center. ( 27027985 )
2016
43
Leiomyosarcoma of cervical stump following subtotal hysterectomy: a case report and review of literature. ( 27048131 )
2016
44
Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. ( 26646120 )
2016
45
Portal vein leiomyosarcoma: a case report and review of the literature. ( 27580598 )
2016
46
Gamma-glutamyltransferase as novel biomarker in patients with uterine leiomyosarcoma. ( 27646551 )
2016
47
TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. ( 26994023 )
2016
48
Metastatic Gastric Polyp Diagnosing Retroperitoneal Leiomyosarcoma. ( 27580773 )
2016
49
Liver and Vena Cava En Bloc Resection for an Invasive Leiomyosarcoma Causing Budd-Chiari Syndrome, Under Veno-Venous Bypass and Liver Hypothermic Perfusion : Liver Hypothermic Perfusion and Veno-Venous Bypass for Inferior Vena Cava Leiomyosarcoma. ( 27431416 )
2016
50
Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures. ( 26768834 )
2016

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Pathogenic rs555607708 GRCh37 Chromosome 22, 29091857: 29091857

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 60)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 8
2 COSM44073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.374C>A p.T125K 8
3 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 8
4 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 8
5 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 8
6 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 8
7 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 8
8 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 8
9 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 8
10 COSM10943 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>C p.D281H 8
11 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 8
12 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 8
13 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 8
14 COSM43871 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.746G>T p.R249M 8
15 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 8
16 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 8
17 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 8
18 COSM44683 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.652G>A p.V218M 8
19 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 8
20 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 8
21 COSM43827 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.581T>C p.L194P 8
22 COSM44076 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.655C>T p.P219S 8
23 COSM10891 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.814G>A p.V272M 8
24 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 8
25 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 8
26 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 8
27 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 8
28 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 8
29 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 8
30 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 8
31 COSM5064 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.44G>A p.R15K 8
32 COSM5923 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.1027-7T>C p.? 8
33 COSM5152 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.388C>T p.R130* 8
34 COSM5124 PTEN soft tissue,smooth muscle,leiomyosarcoma,NS c.1202C>T p.T401I 8
35 COSM516 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.34G>T p.G12C 8
36 COSM521 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.35G>A p.G12D 8
37 COSM534 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.38G>T p.G13V 8
38 COSM532 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.38G>A p.G13D 8
39 COSM520 KRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.35G>T p.G12V 8
40 COSM483 HRAS soft tissue,smooth muscle,leiomyosarcoma,NS c.35G>T p.G12V 8
41 COSM43559 TP53 soft tissue,smooth muscle,leiomyoma,NS c.517G>T p.V173L 4
42 COSM43965 TP53 soft tissue,smooth muscle,leiomyoma,NS c.734G>C p.G245A 4
43 COSM131590 MED12 soft tissue,smooth muscle,leiomyoma,NS c.107T>G p.L36R 4
44 COSM131597 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>T p.G44V 4
45 COSM131595 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>C p.G44A 4
46 COSM131596 MED12 soft tissue,smooth muscle,leiomyoma,NS c.131G>A p.G44D 4
47 COSM131591 MED12 soft tissue,smooth muscle,leiomyoma,NS c.128A>C p.Q43P 4
48 COSM131593 MED12 soft tissue,smooth muscle,leiomyoma,NS c.130G>T p.G44C 4
49 COSM131618 MED12 soft tissue,smooth muscle,leiomyoma,NS c.100-8T>A p.E33_D34insPQ 4
50 COSM131594 MED12 soft tissue,smooth muscle,leiomyoma,NS c.130G>A p.G44S 4

Copy number variations for Leiomyosarcoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 CAPN6 CDK4 CHEK2 DES IGF2 KIT
2
Show member pathways
13 IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3
Show member pathways
12.9 CDK4 KIT MDM2 PDGFRA PDGFRB PGR
4
Show member pathways
12.64 KIT MDM2 PDGFRA PDGFRB TP53
5 12.47 CDK4 KIT MDM2 PDGFRA PDGFRB TP53
6 12.42 MDM2 PDGFRA PDGFRB TP53 VIM
7 12.4 CDK4 CHEK2 MDM2 TP53 VIM
8 12.32 CDK4 CHEK2 PDGFRA PDGFRB TP53
9
Show member pathways
12.31 CDK4 CHEK2 MDM2 TP53
10 12.3 CDK4 CHEK2 MDM2 TP53
11
Show member pathways
12.22 CAPN6 CHEK2 MDM2 PDGFRA PDGFRB TP53
12
Show member pathways
12.17 CDK4 CHEK2 MDM2 TP53
13 12.1 CDK4 FH KIT MDM2 PDGFRA PDGFRB
14 12.06 CDK4 CHEK2 MDM2 TP53
15
Show member pathways
12.02 CDK4 MDM2 PDGFRA PDGFRB TP53
16 11.99 CDK4 CHEK2 MDM2 TP53
17 11.73 PDGFRA S100B VIM
18 11.67 CDK4 MDM2 TP53
19
Show member pathways
11.66 CHEK2 MDM2 TP53
20 11.65 ACTC1 DES VIM
21
Show member pathways
11.64 KIT PDGFRA PDGFRB
22 11.55 KIT PDGFRA PDGFRB TP53
23 11.54 CHEK2 MDM2 TP53
24
Show member pathways
11.49 CHEK2 MDM2 TP53
25 11.39 ACTC1 IGF2 KIT PDGFRA
26 11.22 CDK4 CHEK2 MDM2 TP53
27 11.21 CDK4 MDM2 TP53
28 11.15 CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
29 11.1 CDK4 CHEK2 MDM2 TP53
30 10.27 CHEK2 TP53

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.95 ACTC1 KIT MDM2 TP53 VIM
2 protein autophosphorylation GO:0046777 9.87 CHEK2 KIT PDGFRA PDGFRB
3 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.79 KIT PDGFRA PDGFRB
4 cell chemotaxis GO:0060326 9.78 KIT PDGFRA PDGFRB
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.77 KIT PDGFRA PDGFRB
6 positive regulation of fibroblast proliferation GO:0048146 9.73 CDK4 PDGFRA PDGFRB
7 phosphatidylinositol-mediated signaling GO:0048015 9.73 KIT PDGFRA PDGFRB TP53
8 muscle filament sliding GO:0030049 9.7 ACTC1 DES VIM
9 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.63 KIT PDGFRA PDGFRB
10 replicative senescence GO:0090399 9.62 CHEK2 TP53
11 retina vasculature development in camera-type eye GO:0061298 9.59 PDGFRA PDGFRB
12 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.58 PDGFRA PDGFRB
13 metanephric mesenchyme development GO:0072075 9.58 PDGFRB WT1
14 cellular response to gamma radiation GO:0071480 9.58 CHEK2 MDM2 TP53
15 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.56 CHEK2 MDM2 MUC1 TP53
16 metanephric S-shaped body morphogenesis GO:0072284 9.54 PDGFRB WT1
17 negative regulation of cell cycle arrest GO:0071157 9.54 CDK4 CHEK2 MDM2
18 cellular response to actinomycin D GO:0072717 9.51 MDM2 TP53
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.5 CHEK2 MUC1 TP53
20 positive regulation of cell proliferation GO:0008284 9.5 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
21 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.49 PDGFRA PDGFRB
22 metanephric glomerular capillary formation GO:0072277 9.48 PDGFRA PDGFRB
23 cardiac myofibril assembly GO:0055003 9.33 ACTC1 PDGFRA PDGFRB
24 positive regulation of phospholipase C activity GO:0010863 8.8 KIT PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 CHEK2 DES MDM2 S100B TP53 VIM
2 nucleotide binding GO:0000166 9.55 CDK4 CHEK2 KIT PDGFRA PDGFRB
3 p53 binding GO:0002039 9.5 MDM2 MUC1 TP53
4 platelet-derived growth factor binding GO:0048407 9.43 PDGFRA PDGFRB
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.43 KIT PDGFRA PDGFRB
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 KIT PDGFRA PDGFRB
7 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRA PDGFRB
8 protein binding GO:0005515 10.3 CDK4 CHEK2 DES ENO2 FH IGF2

Sources for Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....